Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61


Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.

Wiederhold NP, Locke JB, Daruwala P, Bartizal K.

J Antimicrob Chemother. 2018 Nov 1;73(11):3063-3067. doi: 10.1093/jac/dky280.


Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Locke JB, Almaguer AL, Donatelli JL, Bartizal KF.

Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018.


Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.


In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.

Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD.

J Antimicrob Chemother. 2017 May 1;72(5):1355-1358. doi: 10.1093/jac/dkx008.


Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin.

Ong V, Hough G, Schlosser M, Bartizal K, Balkovec JM, James KD, Krishnan BR.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6872-6879. doi: 10.1128/AAC.00701-16. Print 2016 Nov.


Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.

Locke JB, Almaguer AL, Zuill DE, Bartizal K.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6100-7. doi: 10.1128/AAC.00620-16. Print 2016 Oct.


CD101: a novel long-acting echinocandin.

Zhao Y, Perez WB, Jiménez-Ortigosa C, Hough G, Locke JB, Ong V, Bartizal K, Perlin DS.

Cell Microbiol. 2016 Sep;18(9):1308-16. doi: 10.1111/cmi.12640. Epub 2016 Jul 22.


Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.

Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF.

Diagn Microbiol Infect Dis. 2015 Feb;81(2):112-8. doi: 10.1016/j.diagmicrobio.2014.08.011. Epub 2014 Aug 30.


Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.

Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P.

Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29.


Tedizolid for the management of human infections: in vitro characteristics.

Locke JB, Zurenko GE, Shaw KJ, Bartizal K.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Review.


In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P.

Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22.


Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.

Choi S, Im W, Bartizal K.

Antimicrob Agents Chemother. 2012 Sep;56(9):4713-7. doi: 10.1128/AAC.00346-12. Epub 2012 Jun 19.


In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.

Gill CJ, Abruzzo GK, Flattery AM, Misura AS, Bartizal K, Hickey EJ.

Antimicrob Agents Chemother. 2007 Sep;51(9):3434-6. Epub 2007 Jul 2.


Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB.

Nature. 2006 May 18;441(7091):358-61.


The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Salowe SP, Zaller DM, Scolnick EM, Schmatz DM, Bartizal K, Hermes JD, MacCoss M, Chapman KT.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. Epub 2005 Dec 9.


Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, Motyl M.

Antimicrob Agents Chemother. 2005 Sep;49(9):3616-23.


Anthrax lethal factor inhibition.

Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Patel SB, Wisniewski D, Scapin G, Salowe SP, Zaller DM, Chapman KT, Scolnick EM, Schmatz DM, Bartizal K, MacCoss M, Hermes JD.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7958-63. Epub 2005 May 23.


Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N.

Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):470-4. Epub 2003 Jul 23.


Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.

Hicks PS, Pelak B, Woods GL, Bartizal KF, Motyl M.

Clin Microbiol Infect. 2002 Nov;8(11):753-7.


Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.

Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):183-7.


Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.

Pelak BA, Woods GL, Teppler H, Friedland I, Bartizal K, Motyl M.

J Chemother. 2002 Jun;14(3):227-33.


Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H.

Antimicrob Agents Chemother. 2000 Sep;44(9):2310-8.


Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase.

Mandala SM, Thornton RA, Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG, Harris G, Abruzzo GK, Flattery AM, Gill CJ, Bartizal K, Dreikorn S, Kurtz MB.

J Biol Chem. 1998 Jun 12;273(24):14942-9.


Antibacterial activity of lonchocarpol A.

Salvatore MJ, King AB, Graham AC, Onishi HR, Bartizal KF, Abruzzo GK, Gill CJ, Ramjit HG, Pitzenberger SM, Witherup KM.

J Nat Prod. 1998 May;61(5):640-2.


Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB.

Antimicrob Agents Chemother. 1997 Nov;41(11):2471-9.


Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K.

Antimicrob Agents Chemother. 1997 Nov;41(11):2333-8.


In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J.

Antimicrob Agents Chemother. 1997 Nov;41(11):2326-32.


Evaluation of experimental therapeutics in a new mouse model of Helicobacter felis utilizing 16S rRNA polymerase chain reaction for detection.

Smith JG, Kong L, Abruzzo GK, Gill CJ, Flattery AM, Scott PM, Silver L, Kropp H, Bartizal K.

Scand J Gastroenterol. 1997 Apr;32(4):297-302.


Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM.

Infect Immun. 1996 Aug;64(8):3244-51.


New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.

Flattery AM, Abruzzo GK, Gill CJ, Smith JG, Bartizal K.

Antimicrob Agents Chemother. 1996 Jul;40(7):1604-9.


Carbazate as a glycine bioisostere in restricticin.

VanMiddlesworth F, Milligan J, Bartizal K, Dufresne C, Onishi J, Abruzzo G, Patchett A, Wilson K.

J Antibiot (Tokyo). 1996 Mar;49(3):329-31. No abstract available.


A sensitive and specific PCR method to detect Helicobacter felis in a conventional mouse model.

Kong L, Smith JG, Bramhill D, Abruzzo GK, Bonfiglio C, Cioffe C, Flattery AM, Gill CJ, Lynch L, Scott PM, Silver L, Thompson C, Kropp H, Bartizal K.

Clin Diagn Lab Immunol. 1996 Jan;3(1):73-8.


PCR detection of colonization by Helicobacter pylori in conventional, euthymic mice based on the 16S ribosomal gene sequence.

Smith JG, Kong L, Abruzzo GK, Gill CJ, Flattery AM, Scott PM, Bramhill D, Cioffe C, Thompson CM, Bartizal K.

Clin Diagn Lab Immunol. 1996 Jan;3(1):66-72.


In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.

Gill CJ, Abruzzo GK, Flattery AM, Smith JG, Jackson J, Kong L, Wilkening R, Shankaran K, Kropp H, Bartizal K.

J Antibiot (Tokyo). 1995 Oct;48(10):1141-7.


Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Krupa D, Pikounis VB, Kropp H, Bartizal K.

Antimicrob Agents Chemother. 1995 May;39(5):1077-81.


In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

Bartizal K, Scott T, Abruzzo GK, Gill CJ, Pacholok C, Lynch L, Kropp H.

Antimicrob Agents Chemother. 1995 May;39(5):1070-6.


Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives.

Ponpipom MM, Girotra NN, Bugianesi RL, Roberts CD, Berger GD, Burk RM, Marquis RW, Parsons WH, Bartizal KF, Bergstom JD, et al.

J Med Chem. 1994 Nov 11;37(23):4031-51.


Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.

McFadden DC, Powles MA, Smith JG, Flattery AM, Bartizal K, Schmatz DM.

Infect Immun. 1994 Nov;62(11):4887-92.


Pneumocandin D0, a new antifungal agent and potent inhibitor of Pneumocystis carinii.

Morris SA, Schwartz RE, Sesin DF, Masurekar P, Hallada TC, Schmatz DM, Bartizal K, Hensens OD, Zink DL.

J Antibiot (Tokyo). 1994 Jul;47(7):755-64.


Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Bouffard FA, Zambias RA, Dropinski JF, Balkovec JM, Hammond ML, Abruzzo GK, Bartizal KF, Marrinan JA, Kurtz MB, McFadden DC, et al.

J Med Chem. 1994 Jan 21;37(2):222-5. No abstract available.


Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, Body BA, Frey C, Hall G, Roberts GD, et al.

Antimicrob Agents Chemother. 1993 Jan;37(1):39-45.


Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Espinel-Ingroff A, Kish CW Jr, Kerkering TM, Fromtling RA, Bartizal K, Galgiani JN, Villareal K, Pfaller MA, Gerarden T, Rinaldi MG, et al.

J Clin Microbiol. 1992 Dec;30(12):3138-45.


Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.

Schmatz DM, Abruzzo G, Powles MA, McFadden DC, Balkovec JM, Black RM, Nollstadt K, Bartizal K.

J Antibiot (Tokyo). 1992 Dec;45(12):1886-91.


In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Bartizal K, Abruzzo G, Trainor C, Krupa D, Nollstadt K, Schmatz D, Schwartz R, Hammond M, Balkovec J, Vanmiddlesworth F.

Antimicrob Agents Chemother. 1992 Aug;36(8):1648-57.


Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach.

Zambias RA, Hammond ML, Heck JV, Bartizal K, Trainor C, Abruzzo G, Schmatz DM, Nollstadt KM.

J Med Chem. 1992 Jul 24;35(15):2843-55.


Sphingofungins A, B, C, and D; a new family of antifungal agents. I. Fermentation, isolation, and biological activity.

VanMiddlesworth F, Giacobbe RA, Lopez M, Garrity G, Bland JA, Bartizal K, Fromtling RA, Polishook J, Zweerink M, Edison AM, et al.

J Antibiot (Tokyo). 1992 Jun;45(6):861-7.


Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP).

Balkovec JM, Black RM, Hammond ML, Heck JV, Zambias RA, Abruzzo G, Bartizal K, Kropp H, Trainor C, Schwartz RE, et al.

J Med Chem. 1992 Jan;35(1):194-8. No abstract available.


L-687,781, a new member of the papulacandin family of beta-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation, and biological activity.

VanMiddlesworth F, Omstead MN, Schmatz D, Bartizal K, Fromtling R, Bills G, Nollstadt K, Honeycutt S, Zweerink M, Garrity G, et al.

J Antibiot (Tokyo). 1991 Jan;44(1):45-51.

Supplemental Content

Loading ...
Support Center